If the science was sketchy or even 'meh' on top of horrible mgmt, then yeah I agree, cut loose.  But the value of this investment's underlying science is so jaw-dropping, so disruptive, so blockbuster that it doesn't make sense to cut loose at these fire-sale prices. Might as well wait for an angel investor or a miracle non-(or minimally) dilutive funding of P3 trials.  That sorry fact doesn't give away our rights to express our extreme disappointment at the massive and ongoing lost opportunity, piling up like a multi-billion-dollar  train wreak every month that apabetalone is not advanced to commercialization. Okay, yeah, so maybe we're waiting on a miracle. They can happen.  If I saw credible management put in place then I'd even be considering a bigger position.  

Let us pray...